Ironwood Pharmaceuticals, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also reports fourth-quarter results. Ironwood is a GI-focused biopharmaceutical company whose principal commercial asset is LINZESS (linaclotide), marketed in the U.S. through an equal profit-and-loss-sharing collaboration with AbbVie and internationally through partners.
Key financial results
| Metric | FY2020 | FY2019 | Change / context |
|---|---|---|---|
| Total revenue | $389.5 million | $428.4 million | Down 9%, mainly as API sales fell following transfer of manufacturing responsibilities to partners. |
| Collaborative arrangements revenue | $381.5 million | $379.7 million | Nearly flat overall; U.S. LINZESS collaboration revenue rose 13% to $368.6 million. |
| API sales | $8.0 million | $48.8 million | Down $40.8 million, chiefly due to the Astellas supply transition. |
| Operating income | $142.9 million | $120.1 million | Approximate operating margin was 36.7%, versus 28.0% in 2019. |
| Net income | $106.2 million | $21.5 million | Diluted EPS was $0.66 versus $0.14. FY2019 included a $37.4 million discontinued-operations loss. |
| Operating cash flow | $168.8 million | $10.7 million | Cash from continuing operations was $168.8 million in 2020; 2019 continuing operations used $0.6 million. |
| Cash and cash equivalents | $362.6 million | $177.0 million | Up $185.5 million during 2020. |
| Debt | $520.7 million principal; $430.3 million net carrying amount | $520.7 million principal; $408.0 million net carrying amount | Convertible notes mature in 2022, 2024 and 2026. |
Approximate net margin was 27.3% in 2020 versus 5.0% in 2019. Fourth-quarter 2020 revenue was $116.7 million and net income was $43.2 million, compared with fourth-quarter 2019 revenue of $126.3 million and net income of $47.9 million.
At year-end, current assets were $495.8 million and current liabilities $32.2 million; working capital excluding deferred revenue was $463.7 million. Total assets were $559.2 million, total liabilities $496.6 million and stockholders’ equity $62.6 million. Cash from operations and $18.5 million of financing cash inflows were partly offset by $1.8 million of capital expenditures. The filing states cash on hand was expected to support projected operating needs for at least 12 months from issuance of the financial statements.
Material changes and operating developments
- U.S. LINZESS collaboration revenue increased by $43.2 million, driven primarily by prescription demand and lower collaboration selling costs during the pandemic. It accounted for the large majority of total revenue.
- Research and development expense declined 23% to $88.1 million; selling, general and administrative expense declined 19% to $140.0 million. Lower costs reflected program changes, lower separation-related expenses, and reduced travel and other costs.
- Total expenses included $15.4 million of restructuring charges, primarily tied to a workforce reduction of approximately 100 employees following the IW-3718 decision. The company also recorded approximately $1.2 million of fixed-asset impairment within restructuring expenses.
- Ironwood and AbbVie discontinued MD-7246 after its Phase II trial failed to meet primary and key secondary endpoints. Ironwood discontinued IW-3718 after a Phase III trial failed its planned early efficacy criteria, including the primary heartburn-severity endpoint.
- The U.S. FDA expanded LINZESS prescribing information in September 2020 to describe its effects on abdominal bloating, pain and discomfort in adult IBS-C patients. Pediatric studies remain ongoing.
- Ironwood completed the transfer of linaclotide manufacturing responsibilities to Astellas and AstraZeneca. The company reported that it was no longer responsible for supplying linaclotide API, finished drug product or finished goods to partners as of year-end.
Outlook, risks and unusual items
- Outlook: The filing provides no specific revenue or earnings guidance. Management’s stated priorities in the 2021 strategy refresh were to maximize LINZESS, build an innovative GI pipeline and deliver sustained profits and cash flow. IW-3300 remained in preclinical development for visceral-pain conditions.
- Management expected cost savings from the workforce reduction and discontinued IW-3718 spending. The company cautioned that future results and cash flows depend heavily on U.S. LINZESS demand and may fluctuate with prescription trends, wholesaler purchasing and partner-reported costs.
- COVID-19: The pandemic affected commercial activity, clinical-trial enrollment and operations; Ironwood reported approximately $2.4 million of incremental pandemic-related expenses in 2020. No significant disruption to U.S. LINZESS supply had occurred as of the filing, but future impacts remained uncertain.
- Concentration and partner dependence: U.S. LINZESS revenue is shared with AbbVie, which supplies key sales and financial information used in Ironwood’s reporting. AbbVie accounted for 76% of 2020 revenue; Astellas accounted for 1%. Partner execution, product access, reimbursement and supply continuity are significant risks.
- Patent competition: Settlement agreements with five generic manufacturers provide for potential generic entry for 145 mcg and 290 mcg LINZESS as early as March 2029, subject to FDA approval and specified conditions; one settlement covers 72 mcg entry beginning in August 2030.
- Debt and taxes: The $120.7 million remaining 2022 notes create a nearer-term maturity, followed by $200 million principal in each of 2024 and 2026. A full valuation allowance remained against $395.0 million of deferred tax assets; federal NOLs were approximately $1.1 billion, subject to potential limitations.
- Subsequent event: CEO Mark Mallon notified the company on February 4, 2021 that he would resign effective March 12, 2021; President Thomas McCourt was to become interim CEO. The filing states the resignation was not due to a disagreement with the company.
- The company reported no material legal proceedings. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether LINZESS prescription demand, U.S. collaboration revenue and partner-reported net-profit calculations remain on track, including the effect of reimbursement and promotional costs.
- The composition, timing and availability of cash and receivables, including the collection of year-end partner receivables and cash sufficiency beyond management’s stated 12-month outlook.
- Debt repayment or refinancing plans ahead of the 2022 note maturity, and the potential dilution or cash effects of convertible notes and related hedge arrangements.
- Actual savings and remaining obligations following the IW-3718 discontinuation and workforce reduction, and the company’s plans and funding for rebuilding its GI pipeline.
- Progress of LINZESS pediatric studies, generic-entry settlement conditions and patent protection, and any continuing commercial, supply or clinical effects of COVID-19.